Literature DB >> 23481700

The human leukocyte antigen-presented ligandome of B lymphocytes.

Chopie Hassan1, Michel G D Kester, Arnoud H de Ru, Pleun Hombrink, Jan Wouter Drijfhout, Harm Nijveen, Jack A M Leunissen, Mirjam H M Heemskerk, J H Frederik Falkenburg, Peter A van Veelen.   

Abstract

Peptides presented by human leukocyte antigen (HLA) molecules on the cell surface play a crucial role in adaptive immunology, mediating the communication between T cells and antigen presenting cells. Knowledge of these peptides is of pivotal importance in fundamental studies of T cell action and in cellular immunotherapy and transplantation. In this paper we present the in-depth identification and relative quantification of 14,500 peptide ligands constituting the HLA ligandome of B cells. This large number of identified ligands provides general insight into the presented peptide repertoire and antigen presentation. Our uniquely large set of HLA ligands allowed us to characterize in detail the peptides constituting the ligandome in terms of relative abundance, peptide length distribution, physicochemical properties, binding affinity to the HLA molecule, and presence of post-translational modifications. The presented B-lymphocyte ligandome is shown to be a rich source of information by the presence of minor histocompatibility antigens, virus-derived epitopes, and post-translationally modified HLA ligands, and it can be a good starting point for solving a wealth of specific immunological questions. These HLA ligands can form the basis for reversed immunology approaches to identify T cell epitopes based not on in silico predictions but on the bona fide eluted HLA ligandome.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23481700      PMCID: PMC3708169          DOI: 10.1074/mcp.M112.024810

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  57 in total

Review 1.  Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.

Authors:  Gabor Mester; Vanessa Hoffmann; Stefan Stevanović
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

2.  Direct quantitation of MHC-bound peptide epitopes by selected reaction monitoring.

Authors:  Chor Teck Tan; Nathan P Croft; Nadine L Dudek; Nicholas A Williamson; Anthony W Purcell
Journal:  Proteomics       Date:  2011-05-20       Impact factor: 3.984

3.  Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes.

Authors:  Jan H Kessler; Selina Khan; Ulrike Seifert; Sylvie Le Gall; K Martin Chow; Annette Paschen; Sandra A Bres-Vloemans; Arnoud de Ru; Nadine van Montfoort; Kees L M C Franken; Willemien E Benckhuijsen; Jill M Brooks; Thorbald van Hall; Kallol Ray; Arend Mulder; Ilias I N Doxiadis; Paul F van Swieten; Hermen S Overkleeft; Annik Prat; Birgitta Tomkinson; Jacques Neefjes; Peter M Kloetzel; David W Rodgers; Louis B Hersh; Jan W Drijfhout; Peter A van Veelen; Ferry Ossendorp; Cornelis J M Melief
Journal:  Nat Immunol       Date:  2010-12-12       Impact factor: 25.606

Review 4.  MHC-based detection of antigen-specific CD8+ T cell responses.

Authors:  Sine Reker Hadrup; Ton N Schumacher
Journal:  Cancer Immunol Immunother       Date:  2010-02-23       Impact factor: 6.968

5.  Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft.

Authors:  David Laurin; Dalil Hannani; Martine Pernollet; Agnès Moine; Joël Plumas; Jean-Claude Bensa; Jean-Yves Cahn; Frédéric Garban
Journal:  Transfusion       Date:  2009-10-15       Impact factor: 3.157

6.  Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.

Authors:  Gemma G Kenter; Marij J P Welters; A Rob P M Valentijn; Margriet J G Lowik; Dorien M A Berends-van der Meer; Annelies P G Vloon; Farah Essahsah; Lorraine M Fathers; Rienk Offringa; Jan Wouter Drijfhout; Amon R Wafelman; Jaap Oostendorp; Gert Jan Fleuren; Sjoerd H van der Burg; Cornelis J M Melief
Journal:  N Engl J Med       Date:  2009-11-05       Impact factor: 91.245

7.  Phospho.ELM: a database of phosphorylation sites--update 2011.

Authors:  Holger Dinkel; Claudia Chica; Allegra Via; Cathryn M Gould; Lars J Jensen; Toby J Gibson; Francesca Diella
Journal:  Nucleic Acids Res       Date:  2010-11-09       Impact factor: 16.971

8.  HSPVdb--the Human Short Peptide Variation Database for improved mass spectrometry-based detection of polymorphic HLA-ligands.

Authors:  Harm Nijveen; Michel G D Kester; Chopie Hassan; Aurélie Viars; Arnoud H de Ru; Machiel de Jager; J H Fred Falkenburg; Jack A M Leunissen; Peter A van Veelen
Journal:  Immunogenetics       Date:  2010-12-02       Impact factor: 2.846

9.  Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences.

Authors:  Christoph T Berger; Jonathan M Carlson; Chanson J Brumme; Kari L Hartman; Zabrina L Brumme; Leah M Henry; Pamela C Rosato; Alicja Piechocka-Trocha; Mark A Brockman; P Richard Harrigan; David Heckerman; Daniel E Kaufmann; Christian Brander
Journal:  J Exp Med       Date:  2010-01-11       Impact factor: 14.307

10.  The immune epitope database 2.0.

Authors:  Randi Vita; Laura Zarebski; Jason A Greenbaum; Hussein Emami; Ilka Hoof; Nima Salimi; Rohini Damle; Alessandro Sette; Bjoern Peters
Journal:  Nucleic Acids Res       Date:  2009-11-11       Impact factor: 16.971

View more
  53 in total

Review 1.  Sizing up the key determinants of the CD8(+) T cell response.

Authors:  David C Tscharke; Nathan P Croft; Peter C Doherty; Nicole L La Gruta
Journal:  Nat Rev Immunol       Date:  2015-10-09       Impact factor: 53.106

2.  Increased diversity of the HLA-B40 ligandome by the presentation of peptides phosphorylated at their main anchor residue.

Authors:  Miguel Marcilla; Adán Alpízar; Manuel Lombardía; Antonio Ramos-Fernandez; Manuel Ramos; Juan Pablo Albar
Journal:  Mol Cell Proteomics       Date:  2013-12-23       Impact factor: 5.911

3.  Unique peptide-binding motif for Mamu-B*037:01: an MHC class I allele common to Indian and Chinese rhesus macaques.

Authors:  Natasja G de Groot; Corrine M C Heijmans; Arnoud H de Ru; Chopie Hassan; Nel Otting; Gaby G M Doxiadis; Frits Koning; Peter A van Veelen; Ronald E Bontrop
Journal:  Immunogenetics       Date:  2013-09-17       Impact factor: 2.846

4.  The first step of peptide selection in antigen presentation by MHC class I molecules.

Authors:  Malgorzata A Garstka; Alexander Fish; Patrick H N Celie; Robbie P Joosten; George M C Janssen; Ilana Berlin; Rieuwert Hoppes; Magda Stadnik; Lennert Janssen; Huib Ovaa; Peter A van Veelen; Anastassis Perrakis; Jacques Neefjes
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-20       Impact factor: 11.205

5.  Naturally processed non-canonical HLA-A*02:01 presented peptides.

Authors:  Chopie Hassan; Eric Chabrol; Lorenz Jahn; Michel G D Kester; Arnoud H de Ru; Jan W Drijfhout; Jamie Rossjohn; J H Frederik Falkenburg; Mirjam H M Heemskerk; Stephanie Gras; Peter A van Veelen
Journal:  J Biol Chem       Date:  2014-12-12       Impact factor: 5.157

Review 6.  The role of proteomics in the age of immunotherapies.

Authors:  Sarah A Hayes; Stephen Clarke; Nick Pavlakis; Viive M Howell
Journal:  Mamm Genome       Date:  2018-07-25       Impact factor: 2.957

7.  Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD).

Authors:  Geert P M Mommen; Christian K Frese; Hugo D Meiring; Jacqueline van Gaans-van den Brink; Ad P J M de Jong; Cécile A C M van Els; Albert J R Heck
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-10       Impact factor: 11.205

8.  Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

Authors:  Dyantha I van der Lee; Rogier M Reijmers; Maria W Honders; Renate S Hagedoorn; Rob Cm de Jong; Michel Gd Kester; Dirk M van der Steen; Arnoud H de Ru; Christiaan Kweekel; Helena M Bijen; Inge Jedema; Hendrik Veelken; Peter A van Veelen; Mirjam Hm Heemskerk; J H Frederik Falkenburg; Marieke Griffioen
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

Review 9.  Current tools for predicting cancer-specific T cell immunity.

Authors:  David Gfeller; Michal Bassani-Sternberg; Julien Schmidt; Immanuel F Luescher
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

10.  Analysis of Major Histocompatibility Complex-Bound HIV Peptides Identified from Various Cell Types Reveals Common Nested Peptides and Novel T Cell Responses.

Authors:  Marijana Rucevic; Georgio Kourjian; Julie Boucau; Renata Blatnik; Wilfredo Garcia Bertran; Matthew J Berberich; Bruce D Walker; Angelika B Riemer; Sylvie Le Gall
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.